Cox Proportional Hazards Regression Models of Risk Factors Associated with Recurrece-free Survival.

<p>Cox Proportional Hazards Regression Models of Risk Factors Associated with Recurrece-free Survival.</p

Kaplan–Meier survival curves for cancer-specific survival of cervical cancer patients receiving neoadjuvant chemotherapy for bulky early stage disease.

<p>The <i>P</i> values were determined by the log-rank test.</p

Kaplan–Meier survival curves for recurrence-free survival of cervical cancer patients receiving neoadjuvant chemotherapy for bulky early stage disease.

<p>The <i>P</i> values were determined by the log-rank test.</p

Patient Baseline Demographic and Clinical Characteristics.

<p>Patient Baseline Demographic and Clinical Characteristics.</p

Subgroup Analysis of Univariate Hazard Ratios of Survival for Hyperglycemia vs Euglycemia Using the Cox Proportional Hazard Model.

<p>Subgroup Analysis of Univariate Hazard Ratios of Survival for Hyperglycemia vs Euglycemia Using the Cox Proportional Hazard Model.</p

Cox Proportional Hazards Regression Models of Risk Factors Associated with Cancer-specific Survival.

<p>Cox Proportional Hazards Regression Models of Risk Factors Associated with Cancer-specific Survival.</p

Univariate and Multivariate Analysis of Factors Associated with Complete Response Following Neoadjuvant Chemotherapy.

<p>Univariate and Multivariate Analysis of Factors Associated with Complete Response Following Neoadjuvant Chemotherapy.</p

Additional file 2: Table S1. of Pretreatment glycemic control status is an independent prognostic factor for cervical cancer patients receiving neoadjuvant chemotherapy for locally advanced disease

Univariate and multivariate Cox analysis of prognostic factors associated with survival for diabetic patients with locally advanced cervical cancer who underwent neoadjuvant chemotherapy and radical hysterectomy. (DOCX 23 kb

Additional file 1: Figure S1. of Pretreatment glycemic control status is an independent prognostic factor for cervical cancer patients receiving neoadjuvant chemotherapy for locally advanced disease

Guide for follow-up and telephone interview. (EPS 650 kb